Eleven Therapeutics

About

Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation.

The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Artificial Intelligence

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology

Business model

B2B

Eleven Therapeutics — Full Company Profile (machine-readable)

Next Generation of RNA Therapeutics

About

Eleven Therapeutics is a startup at the forefront of mRNA therapeutics innovation. The company’s xRNA modality-based pipeline is aimed to create extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. TERÅ is a proprietary high-throughput platform designed to screen thousands of xRNA molecules in order to identify non-canonical elements that possess superior stability and safety characteristics, amenable for a multitude of chronic therapeutic applications, including the newly announced fibrotic disorders.

Facts

Name	Eleven Therapeutics
Slug	eleven-therapeutics
Type	Israeli Startup
Founded	2020
HQ city	Tel Aviv-Yafo
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B
Target customers	[object Object], [object Object], [object Object], [object Object]
Status	active
Current stage	Seed
Public stage	Seed
Total raised (USD)	25,900,000
Last round	Seed (2022-08)
Website	https://eleventx.com/
Israeli Companies Registrar	516183977

Funding rounds (2)

Date	Round	Amount	Lead investors	All investors	Valuation
2020-09	Pre-Seed	Undisclosed	Entrée Capital	Entrée Capital
2022-08	Seed	$22,000,000		NFX Capital, Harel Insurance & Finance

Team (5)

Name	Role	LinkedIn
Prof. Yaniv Erlich
Prof. Greg Hannon
Shaul Ilan
Dr. Adi
Iris Grossman

News mentions (6)

Jan 11, 2024 — www.prnewswire.com: Article
Jan 9, 2024 — www.businesskorea.co.kr: Article
Jul 16, 2023 — www.pharmaceutical-technology.com: Article
Mar 26, 2023 — www.calcalistech.com: Article
Aug 2, 2022 — www.finsmes.com: Article
Feb 7, 2022 — www.biospace.com: Article

About

Funding history · 2 rounds · $25.9M total

Sectors & technology

Highlights

Tags